Ian E. Krop
Advertisement
Articles by Ian E. Krop
44 Results From the Phase 1/2 Study of Patritumab Deruxtecan (HER3-DXd), a HER3-Directed Antibody-Drug Conjugate (ADC), in Patients (pts) With HER3- Expressing Metastatic Breast Cancer (MBC)
ByIan E. Krop,Norikazu Masuda,Toru Mukohara,Shunji Takahashi,Takahiro Nakayama,Kenichi Inoue,Hiroji Iwata,Tatsuya Toyama,Yutaka Yamamoto,Damien Hansra,Masato Takahashi,Akihiko Osaki,Kumiko Koyama,Tatsuya Inoue,Takatoshi Yonekura,Joseph Mostillo,Shoichi Ohwada,Yoshimi Tanaka,David Sternberg,Kan Yonemori
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Sacituzumab Govitecan Combo Reduces Progression, Death By 35% in Metastatic TNBC
2
FDA Approves Liquid Biopsy CDx for Encorafenib Regimen in BRAF V600E+ CRC
3
Median OS Not Yet Reached With New Immunotherapy Combo in 2L Glioblastoma
4
Decoding the Top Moments in Prostate Cancer Management From 2025
5